Modality
ERT
MOA
CAR-T BCMA
Target
PD-L1
Pathway
Tau
DLBCL
Development Pipeline
Preclinical
~Jun 2020
→ ~Sep 2021
Phase 1
~Dec 2021
→ ~Mar 2023
Phase 2
Jun 2023
Phase 2Current
NCT07179807
14 pts·DLBCL
2023-06→TBD·Recruiting
14 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P2/3
Recruit…
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07179807 | Phase 2/3 | DLBCL | Recruiting | 14 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| Polatuximab | Nuvalent | Approved | PD-L1 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 |